ASP7991

Phase 2Small molecule

Astellas

ASP7991 is one of 62 small molecule programs targeting Secondary Hyperparathyroidism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Secondary HyperparathyroidismActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Secondary HyperparathyroidismPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Lorelco

Sanofi

Preclinical

1 3

Activase

Flomax

Epoetin Beta

5 6

ASP7991

Astellas

Phase 2

1 7

Sodium Valproate

AstraZeneca

Preclinical

4 8

Genotropin

EMD Serono

Preclinical

1 9

Tradjenta

Boehringer Ingelheim

Preclinical

1 10

SGLT2 Inhibitor

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease1 trial

Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis

Completed· Astellas logo

Astellas·Phase 1·NCT01872026·14 enrolled

Elderly1 trial

Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT01872013·36 enrolled

Concentration1 trial

A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy Volunteers

Completed· Astellas logo

Astellas·Phase 1·NCT01675518·56 enrolled

Secondary Hyperparathyroidism1 trial

A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Completed· Astellas logo

Astellas·Phase 2·NCT02133404·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ASP7991. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASP7991 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASP7991. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Astellas

ASP7991

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Kidney Disease1 trial

Elderly1 trial

Concentration1 trial

Secondary Hyperparathyroidism1 trial

References

Drug Info

Quick Facts

Related News